Current role of beta-adrenergic blockers in the management of chronic heart failure

American Journal of Medicine

Volumn 110, Issue 7, 2001, Pages 81-94

  Packer, Milton ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL;

BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FLUID RETENTION; HEART BLOCK; HEART FAILURE; HEMODYNAMICS; HUMAN; HYPOTENSION; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0035821233     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(01)00676-3     Document Type: Review

References (84)

1. Plasma norepinephrine in congestive heart failure
2. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
3. Importance of adrenergic nervous system in the support of circulatory function in patients with congestive heart failure
4. Pathophysiology of chronic heart failure
5. Beta-adrenergic blockade in chronic heart failure: Principles, progress, and practice
6. Consensus recommendations for the management of chronic heart failure
7. Inotropic and calcium kinetic effects of calcium channel agonist and antagonist in isolated cardiac myocytes from cardiomyopathic hamsters
8. Beta-adrenergic regulation of constitutive nitric oxide synthase in cardiac myocytes
9. Significance of alpha- and beta-adrenoceptors in catecholamine-induced hypertrophy
10. Nitric oxide triggers programmed cell death (apoptosis) of adult rat ventricular myocytes in culture
11. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway
12. Neural control of renal function: Role of renal alpha adrenoceptors
13. The role of alpha-adrenoceptors in the regulation of renal tubular reabsorption and renin secretion in the rabbit
14. Renal nerve stimulation causes alpha 1-adrenoceptor-mediated sodium retention but not alpha 2-adrenoceptor antagonism of vasopressin
15. Alpha-1 adrenergic stimulation is coupled to cardiac myocyte hypertrophy
16. The alpha 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy
17. Influence of isoproterenol on myocardial energetics. Experimental and clinical investigations
18. Coronary vasoconstriction and catecholamine cardiomyopathy
19. Quantitative structural analysis of the myocardium during physiologic growth and induced cardiac hypertrophy: A review
20. Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: Implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors
21. 2-adrenergic stimulation in animals susceptible for sudden death
22. Epinephrine-induced hypokalemia: The role of beta-adrenoceptors
23. An alpha-1-adrenergic receptor subtype is responsible for delayed afterdepolarizations and triggered activity during simulated ischemia and reperfusion of isolated canine Purkinje fibers
24. Altered myocardial force-frequency relation in human heart failure
25. Adrenergic effects on the biology of the adult mammalian cardiocyte
26. Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage
27. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction
28. Nebivolol increases survival in cardiomyopathic hamsters with congestive heart failure
29. Contribution of α-adrenoceptor activation to the pathogenesis of norepinephrine cardiomyopathy
30. 1-receptor down-regulation in heart failure
31. Alpha-1 adrenergic receptors in the nonfailing and failing human heart
32. Alpha 1-adrenoceptor activity in arterial smooth muscle following congestive heart failure
33. 2-adrenoceptor mediated?
34. Selectivity of the intrinsic sympathomimetic activity of the beta-adrenergic blocking drug bucindolol
35. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats
36. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium
37. Xamoterol in severe heart failure
38. β-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy
39. Presentation of the results of Beta-Blocker Survival (BEST) Trial
40. The effect of beta-adrenergic blockade on patterns of urinary sodium excretion: Studies in normal subjects and in patients with heart disease
41. Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy
42. Carvedilol improves renal hemodynamics in patients with chronic heart failure
43. Long-term β-blockade in dilated cardiomyopathy
44. Long-term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double-blind, randomized study of bucindolol versus placebo
45. Improved exercise hemodynamic status in dilated cardiomyopathy after beta-blockade treatment
46. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: A randomized, double-blind, placebo-controlled study
47. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy
48. Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study
49. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in severe chronic heart failure
50. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease
51. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease
52. Medical therapy can improve the biologic properties of the chronically failing heart: A new era in the treatment of heart failure
53. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol
54. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol
55. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis
56. Do changes in exercise tolerance reflect the clinical response to therapy in patients with heart failure? Implications for the design of clinical trials
57. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: A double-blind, randomized, placebo-controlled trial
58. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial
59. Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy
60. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy
61. Improvement in functional status and better overall treatment effect with metoprolol CR/XL in the MERIT-HF Study
62. A randomized trial of β-blockade in heart failure
63. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomised trial
64. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure
65. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure
66. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
67. Safety and efficacy of carvedilol in severe heart failure
68. Presentation of results of Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial
69. Effect of metoprolol CR/XL in chronic heart failure
70. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF)
71. Effect of carvedilol on morbidity and mortality in patients with chronic heart failure
72. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
73. Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long-term treatment
74. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
75. The effect of digoxin on mortality and morbidity in patients with heart failure
76. End of the oldest controversy in medicine. Are we ready to conclude the debate on digitalis?
77. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart
78. Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure
79. Differential effects of carvedilol and metoprolol on β-adrenergic signalling in cardiac myocytes
80. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade
81. Long-term β-blockade in dilated cardiomyopathy: Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol
82. Overexpression of alpha1B-adrenergic receptor induces left ventricular dysfunction in the absence of hypertrophy
83. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice
84. 2-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis